Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 6 Stomach Neoplasms 1 Resectable Pancreatic Cancer 1 Neoplasms, Basal Cell 1 Locally Advanced Unresectable or Metastatic Solid Tumors 1 Localized Pancreatic Adenocarcinoma 1 Gastroesophageal Adenocarcinoma 1 Colorectal Cancer Metastatic 1 Biliary Tract Neoplasms 1 Ampullary Adenocarcinoma 1

Interventions

Oxaliplatin 42 Fluorouracil 27 Capecitabine 24 pembrolizumab 21 S 1 (combination) 19 Paclitaxel 19 Leucovorin 16 Nivolumab 13 Docetaxel 13 sintilimab 12 Drug Therapy 12 Trastuzumab 11 tislelizumab 10 Cisplatin 10 Irinotecan 9 Bevacizumab 8 trastuzumab deruxtecan 7 spartalizumab 7 XELOX 7 Surgical Procedures, Operative 7 Radiotherapy 7 Hyperthermic Intraperitoneal Chemotherapy 7 Biopsy 7 fludarabine 6 disitamab vedotin 6 Cyclophosphamide 6 lenvatinib 5 apatinib 5 Specimen Handling 5 Ramucirumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Stomach Neoplasms × folfirinox × Clear all

NCT03825861 2020-11-10

FOLFIRINOX

Instituto do Cancer do Estado de São Paulo

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡